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Summary 
 
Background Efavirenz is commonly prescribed for children with HIV infection, yet little is known about risks 
of neuropsychiatric side-effects. We aimed to compare competence (social involvement, activities, and school 
performance) and psychopathology (internalising and externalising problems), cognitive performance 
(intelligence and working memory), and adherence in Tanzanian children on an efavirenz-based versus a non-
efavirenz-based regimen. 
Methods In this multicentre, cross-sectional, observational study, we included consecutive children (aged 6–12 
years) with HIV infection, on combination antiretroviral therapy (cART) for at least 6 months, and with viral 
loads of less than 1000 copies per mL from HIV care clinics of three primary health facilities and three referral 
hospitals in Moshi, Kilimanjaro, Tanzania. Children with acute illnesses, medication switch in the 6 months 
before the study visit, and any history of brain injury or developmental delay before cART initiation were 
excluded. All interviews and assessments were done by trained local research nurses under the supervision of a 
medical doctor. The primary outcomes, competence and psychopathology, were measured with the Child 
Behavior Checklist. We used ANCOVA to assess differences between groups. This study is registered with 
ClinicalTrials.gov, number NCT03227653. 
Findings Between June 19, 2017, and Dec 14, 2017, 141 children were analysed, of whom 72 (51%) used 
efavirenz-based cART and 69 (49%) used non-efavirenz-based cART. After controlling for age, sex, and 
clinical and demographic confounders, we observed lower competence (adjusted mean difference −2·43 [95% 
CI −4·19 to −0·67], p=0·0071), largely driven by lower school performance scores (adjusted mean difference 
−0·91 [–1·42 to −0·40], p=0·00055), in the efavirenz group than in the non-efavirenz group. More total 
(adjusted mean difference 5·96 [95% CI −1·12 to 13·04], p=0·098) and internalising (adjusted mean difference 
2·00 [–0·29 to 4·29], p=0·086) behavioural problems were seen in the efavirenz group than in the non-efavirenz 
group, although these findings were non-significant. No differences were found in externalising problems 
(adjusted mean difference 0·78 [95% CI −1·55 to 3·11], p=0·51). 
Interpretation Our results suggest that treatment with efavirenz in children is associated with a mild increase in 
neuropsychiatric symptoms, especially in children who receive doses higher than or equal to the WHO 
recommended doses for efavirenz. Clinical awareness and adequate follow-up of neuropsychiatric symptoms in 
efavirenz in children remain warranted. 
Funding: Aidsfonds, Radboud university medical center. 
 
Keywords: efavirenz, ART therapy, child, adverse effects, Africa South of the Sahara, central nervous system, 
neuropsychological tests, child behaviour, cognition, treatment adherence and compliance 
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Introduction 
 
In 2017, an estimated 1·8 million children worldwide were living with HIV, of whom 52% received combination 
antiretroviral therapy (cART).
1
 The Tanzanian national HIV guidelines recommend including efavirenz in first-
line cART for children aged 3 years or older.
2,3
 In children, efavirenz has several advantages compared with its 
alternatives nevirapine and ritonavir-boosted lopinavir, including superior antiviral efficacy, simplified co-
treatment for tuberculosis, and lower risks for long-term metabolic and bone complications.
4
Among adults on 
efavirenz, a third reports neuropsychiatric side-effects such as nightmares, depression, and hallucinations.
5
 
Although most of these symptoms decrease after weeks to months, some can persist for years, with negative 
consequences for quality of life, adherence, and treatment discontinuation.
6,7
 Apart from neuropsychiatric 
symptoms, efavirenz has been linked to impaired neurocognitive performance.
8
 In part because of these 
tolerability concerns, the latest WHO guidelines
9
 no longer recommend efavirenz as the general drug of choice 
for people with HIV infection. 
Although children generally seem to tolerate efavirenz well, data about neuropsychiatric side-effects remain 
inconclusive.
10, 11
 Until now, only one clinical trial had published psychiatric data about children on efavirenz. 
By use of a brief behavioural screener, the Strengths and Difficulties Questionnaire (SDQ), the authors observed 
no differences in psychopathology between efavirenz and ritonavir-boosted lopinavir.
12, 13
By contrast, other 
studies
14, 15
 reported high frequencies (36–39%) of neuropsychiatric symptoms. Several case reports14,16,17 also 
described the occurrence of severe symptoms, including psychosis, ataxia, and seizures. These discrepancies 
between studies might be partly explained by the large heterogeneity between cohorts, small sample sizes, or 
lack of validated tools for comprehensive paediatric psychiatric assessments.
11
 Potential long-term 
neuropsychiatric side-effects need to be identified because these symptoms might interfere with 
neurodevelopment and psychosocial maturation. In our study, we aimed to comprehensively assess behaviour 
and cognition in children with HIV infection in Tanzania by use of validated psychiatric tools. Our primary goal 
was to compare competence and psychopathology between children treated with efavirenz-based cART and 
children treated with alternative, non-efavirenz-based cART (nevirapine or ritonavir-boosted lopinavir). Second, 
we aimed to compare cognitive performance and adherence between treatment groups. We hypothesised that 
treatment with efavirenz would be associated with lower competence, more psychopathology, reduced cognitive 
performance, and lower adherence compared with alternative cART. 
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Methods 
 
Study design and participants 
In this multicentre, cross-sectional, observational study, we enrolled consecutive HIV-1-positive children who 
were registered at the HIV clinics at Kilimanjaro Christian Medical Centre (a tertiary referral hospital), Mawenzi 
Regional Hospital (a referral hospital), Kibosho Hospital, Majengo Health Centre, Pasua Health Centre, and 
Kiboriloni Dispensary in Moshi District, Kilimanjaro Region, Tanzania. Inclusion criteria were age 6–12 years, 
presence of a caretaker (parent or guardian who was part of the upbringing of the child), treatment with cART 
for at least 6 months, and an HIV-1 RNA count of less than 1000 copies per mL within 12 months of the study 
visit. Exclusion criteria were acute illnesses, medication switch in the 6 months before the study visit, and any 
history of brain injury or developmental delay before cART initiation. 
The institutional review boards of the Kilimanjaro Christian Medical University College (Moshi, Kilimanjaro, 
Tanzania; number 2028) and the National Institute for Medical Research (Dar es Salaam, Tanzania; number 
2447) approved the study protocol. Written informed consent in Kiswahili from parents or guardians of all 
participants was obtained before enrolment. Children aged 12 years provided oral assent. 
 
Procedures 
An overview of the study methods and procedures is provided in the appendix (p 20). Caretakers completed an 
extensive questionnaire on the demographic and socioeconomic status of the household, HIV disclosure, and the 
health status of the child. Clinical data, including HIV-1 RNA results, were obtained retrospectively from the 
child's clinical file. We assessed nutrition using height and body-mass index for age-adjusted Z scores (2007 
WHO growth reference data for children and adolescents aged 5–19 years). 
For behavioural assessments, we used the Child Behavior Checklist for ages 6–18 years (CBCL/6–18). The 
CBCL is a standardised 120-item questionnaire that provides a comprehensive caretaker report of a child's 
competence, and behavioural and emotional problems.
18
 The competence section of the CBCL includes 
questions on the child's activities (sports, hobbies, and jobs), social involvement (organisations and friends), and 
school performance (grades and special classes). The problem section consists of syndrome scores that together 
yield an internalising (anxiety or depression, withdrawn behaviour, or somatic complaints) and externalising 
(rule-breaking or aggressive behaviour) problem score. The total problem score is the sum of all problem items. 
Four main scores can be calculated: total competence, total problems, internalising problems, and externalising 
problems. Raw scores were converted into age-specific, sex-specific, and (Kenyan) population-specific T scores 
to calculate the number of children within the borderline clinical range.
18
 The CBCL is available in Kiswahili 
and has been previously applied in HIV-positive children in sub-Saharan Africa.
19
 
 
We applied Raven's Coloured Progressive Matrices (RCPM) and the digit span test to assess cognitive 
performance. RCPM was used to measure general non-verbal cognitive ability. RCPM consists of 36 multiple-
choice coloured matrices in which items are ordered by increasing difficulty. RCPM is non-verbal, easy, and 
rapid to administer and score, and has been validated for use in children living in Kenya.
20
 
The digit span test (from the Wechsler Intelligence Scale for Children-III) was used to measure short-term and 
working memory.
21
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A string of numbers was read out to the child, who was asked to repeat them in the same order (digit forwards) 
or reversed order (digit backwards). The test was discontinued if the child failed on two consecutive trials. The 
total score corresponds to the maximum number of digits the child repeated correctly. The digit span test has 
been used in HIV-positive children in sub-Saharan Africa.
22
 
For adherence, we used a questionnaire designed by the Pediatric European Network for Treatment of AIDS.
23
 
To determine non-adherence, caretakers were asked how many times the child had missed his or her medication 
in the previous 3 days. Next, caretakers marked adherence since the last clinical visit on a visual analogue scale. 
In addition, structured questions were asked about other aspects of cART adherence. Non-adherence was defined 
as one or more missed doses over the previous 3 days or marking less than 100% adherence since the last clinical 
visit on the visual analogue scale.  
 
Finally, we applied a CNS symptom checklist with symptoms that have been linked to efavirenz in the scientific 
literature.
7,11
 Caretakers and children were asked whether the child had experienced any of these symptoms in 
the week before the study visit.Interviews and cognitive assessments were done by six local research nurses, who 
were experienced in paediatric HIV treatment and counselling. During a 1-week programme, a Dutch medical 
doctor (LVdW) and a Tanzanian paediatrician (DNM) trained the research nurses in conducting the interview 
and cognitive assessments. The research nurses were supervised by LVdW or DNM throughout the study period. 
 
Before enrolment, children were screened by their own physician or the study doctor for acute illnesses and signs 
of gross developmental delay. The study visit consisted of two parts. To minimise information bias, caretakers 
were informed about the study background (CNS side-effects of HIV drugs) and procedures, without disclosing 
our hypothesis. After informed consent, a research nurse interviewed the caretaker and child on adherence and 
general wellbeing. Next, a second research nurse interviewed the caretaker about demographic and clinical 
parameters, and read out the items of the CBCL, while the initial nurse continued with cognitive assessment of 
the child. To optimise cognitive test performance, all visits took place in quiet, private rooms and were 
completed before 1300 h. Data were stored securely and anonymously in the Castor Electronic Data Capture 
programme (Amsterdam, Netherlands). 
 
Outcomes 
Primary outcome measures were competence and psychopathology (internalising and externalising symptoms), 
as defined by the CBCL. Secondary outcome measures were non-verbal cognitive ability, short-term and 
working memory, and non-adherence. Finally, we added CNS symptoms linked to efavirenz in the scientific 
literature as exploratory outcomes. The characteristics of the outcome variables of this study are presented in the 
appendix (p 13). 
 
Data analysis 
The study required 128 participants (64 participants per group) to detect a medium effect difference in CBCL 
total problem scores (Cohen's f=0·25, equal to a difference of 3·9 in CBCL total problem T scores),
19
 with 80% 
power and α set at 0·05. We compared general characteristics between the efavirenz group and non-efavirenz 
group using Student's t test (or Mann-Whitney U test) for continuous variables and Pearson's χ2 test (or Fisher's 
6 
 
exact test) for categorical variables. We used ANCOVA to assess between-group differences in the raw main 
scores (total competence, total problems, internalising problems, and externalising problems). Significant 
differences were assessed by post-hoc ANCOVA for the individual competence or syndrome scores (eg, anxiety 
or depression for internalising problems). We assessed between-group differences in cognitive performance 
scores with ANCOVA and in non-adherence with Pearson's χ2 test. We analysed the presence of CNS symptoms 
using logistic regression models. The following covariates were included because of group differences or their 
clinical relevance in disease severity and mental health: age, sex, parental loss, HIV disclosure, previous hospital 
admission, history of tuberculosis treatment, previous treatment failure, and cART duration. During data 
collection, we discovered that 28 (39%) of 71 children received lower efavirenz doses than recommended by 
WHO.
3
 Thereafter, we decided to add a subgroup analysis in which children who were prescribed lower 
efavirenz doses than recommended by WHO were excluded. We analysed data using SPSS Statistics, version 25. 
 
This study is registered with ClinicalTrials.gov, number NCT03227653. 
 
Role of the funding source 
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing 
of the report. The corresponding author had full access to all the data in the study and had final responsibility for 
the decision to submit for publication. 
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Results 
Between June 19, 2017, and Dec 14, 2017, 144 children were enrolled at the six study sites. Three children were 
excluded from analysis because of age less than 6 years, unreported severe developmental delay, and cART 
switch the week before the study visit (figure). 141 children were analysed, of whom 72 (51%) used efavirenz-
based cART and 69 (49%) used non-efavirenz-based cART. Groups were balanced for age, sex, and nutritional 
status parameters (table 1). Socioeconomic characteristics did not differ between groups (appendix p 6). Children 
in the non-efavirenz group used cART for a longer time (p<0·0001), had a more advanced WHO clinical stage at 
start of cART (p=0·011), had more often experienced previous treatment failure (p<0·0001), and had more often 
been admitted to the hospital (p=0·0016) than children in the efavirenz group. Children in the efavirenz group 
more often had received tuberculosis treatment (p=0·022) and had more often had their own HIV status 
disclosed (p=0·016) than children in the non-efavirenz group. In addition, we observed a non-significant higher 
prevalence of parental loss in the efavirenz group than in the non-efavirenz group (p=0·078). With the exception 
of co-trimoxazole (table 1), no relevant co-medication was used. At the time of analysis, none of the children 
was undergoing tuberculosis treatment. Ten (14%) of 69 children in the non-efavirenz group had previously 
discontinued efavirenz. Efavirenz had been switched to nevirapine in three (30%) of ten children or to ritonavir-
boosted lopinavir in seven (70%) of ten children after a median of 407 days (IQR 179–975) for the following 
reasons: treatment failure (seven [70%] of ten children), neuropsychiatric side-effects (one [10%] of ten 
children), end of tuberculosis treatment (one [10%] of ten children), and unspecified (one [10%] of ten children).
8 
 
 
Figure Study overview 
cART=combination antiretroviral therapy. *The efavirenz dose (mg/kg) could not be determined for one of the participants because of missing bodyweight data. 
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 Table 1. Clinical and demographic characteristics  
Characteristic 
Non-efavirenz 
(n = 69) 
Efavirenz 
(n = 72) 
P-value 
Age, years 9·4 (1·8) 9·9 (1·9) 0·094 
Sex   0·61 
Male 33 (48%) 31 (43%) ·· 
Female 36 (52%) 41 (57%) ·· 
WHO BMI z-score* -0·80 (1·09) -0·84 (1·03) 0·81 
WHO height z-score* -1·00 (0·80) -1·16 (1·04) 0·33 
HIV-RNA <40 copies per mL 54 (78%) 54 (75%) 0·69 
Time since last HIV-RNA measurement, median (IQR) days 100 (56-168) 133 (57-198) 0·074 
Vertical transmission 69 (100%) 72 (100%) ·· 
WHO clinical stage at start cART    
Stage 1 10/68 (15%) 9/70 (13%) 0·011 
Stage 2 16/68 (24%) 29/70 (41%)  
Stage 3 21/68 (31%) 25/70 (36%)  
Stage 4 21/68 (31%) 7/70 (10%)  
Prior treatment failure† 23 (33%) 1 (1%) <0·0001 
Time on cART, median (IQR) years 7·6 (5·4-8·7) 3·5 (2·1-5·6) <0·0001 
Time on efavirenz, median (IQR) years ·· 3·1 (2·0-5·1) ·· 
Prior efavirenz discontinuation 10 (14%) ·· ·· 
cART backbone    
abacavir + lamivudine 23 (33%) 17 (24%) 0·11 
zidovudine + lamivudine 45 (65%) 52 (72%)  
tenofovir disproxil fumarate + lamivudine 0 (0) 3 (4%)  
zidovudine + abacavir + lamivudine 1 (1%) 0 (0)  
cART 3rd drug    
nevirapine 43 (62%) ·· ·· 
lopinavir-ritonavir 26 (37%) ··  
History of tuberculosis treatment 12 (17%) 25 (35%) 0·022 
Co-trimoxazol treatment 33 (48%) 36 (50%) 0·95 
Previous hospital admission‡ 53 (77%) 36 (50%) 0·0016 
Caretaker’s relationship    
Parent 49 (71%) 41 (57%) 0·36 
Relative 16 (23%) 25 (35%)  
Orphanage caretaker 2 (3%) 2 (3%)  
Other 2 (3%) 4 (6%)  
Parental loss    
None (both alive) 44 (64%) 33 (46%) 0·078 
Single 19 (28%) 26 (36%)  
Double 6 (9%) 13 (18%)  
School attendance    
Nursery school 8 (12%) 10 (14%) 0·50 
Primary school 61 (88%) 60 (83%)  
No school 0 (0) 2 (3%)  
HIV-status disclosed 13 (19%) 27 (38%) 0·016 
Data are mean (SD), n (%), median (IQR), or n/N (%). Data were analysed with Student's t test (or Mann-
Whitney U test) for continuous variables and Pearson's χ2 test (or Fisher's exact) for categorical variables. 
cART=combination antiretroviral therapy. 
* Z scores calculated using WHO 2007 growth reference data for children and adolescents aged 5–19 years. 
† Defined as any immunological, virological, or clinical failure documented in the medical file. 
‡ Defined as any previous hospital admission reported by the caretaker or documented in the medical file. 
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Overall, 15 (22%) of 69 children in the non-efavirenz group and 21 (30%) of 71 children in the efavirenz group 
scored below the normal range for total competence (defined as scores below the 16th age-specific, sex-specific, 
and Kenyan population-specific percentile; appendix p 7). Table 2 shows the mean (SD) raw scores on the 
CBCL per treatment group, as well as the unadjusted and the confounder-adjusted models. In general, the 
covariates age and duration of cART had the largest effect on the confounder-adjusted models (appendix p 17). 
Children in the efavirenz group scored lower than children in the non-efavirenz group on the competence scale 
(adjusted mean difference −2·43 [95% CI −4·19 to −0·67], p=0·0071). Post-hoc analyses showed that these 
lower competence scores were primarily driven by lower school performance scores (adjusted mean difference 
−0·91 [95% CI −1·42 to −0·40], p=0·00055). 
 
Except for internalising problems, psychopathology was relatively uncommon in our study population. Scores 
above the normal range (defined as scores above the 84th age-specific, sex-specific, and Kenyan population-
specific percentile; appendix p 7) were seen in eight (12%) of 69 children in the non-efavirenz group versus nine 
(13%) of 72 children in the efavirenz group for total problems, in 17 (25%) of 69 children versus 22 (31%) of 72 
children for internalising problems, and in six (9%) of 69 children versus seven (10%) of 72 children for 
externalising problems. We observed non-significantly higher total problem scores (adjusted mean difference 
5·96 [95% CI −1·12 to 13·04], p=0·098) and higher internalising problem scores (adjusted mean difference 2·00 
[–0·29 to 4·29], p=0·086) in the efavirenz group than in the non-efavirenz group, but we found no differences in 
externalising problems (adjusted mean difference 0·78 [–1·55 to 3·11], p=0·51). 
 
Using South African RCPM norm scores for children, which measure general non-verbal cognitive ability, four 
(6%) of 69 children in the non-efavirenz group and two (3%) of 72 children in the efavirenz group scored below 
the 10th percentile (appendix p 8), indicating that non-verbal cognitive ability was largely unaffected in both 
groups. We found no group differences in general non-verbal cognitive ability, and we did not observe an effect 
of efavirenz on short-term memory or working memory (table 2). Non-adherence was reported by 24 (35%) of 
69 children in the non-efavirenz group and 20 (28%) of 72 children in the efavirenz group (p=0·47; appendix p 
9). Additional information on adherence is summarised in the appendix (p 9). 
Finally, we explored the presence of CNS symptoms that have been linked to efavirenz in the scientific literature 
(table 3; appendix p 18). In accordance with the results from the CBCL, children in the efavirenz group more 
frequently reported problems paying attention at school (19 [26%] of 72 children vs eight [12%] of 69 children), 
depressed or anxious feelings (17 [24%] of 72 children vs six [9%] of 69 children), and feelings of uneasiness 
(20 [28%] of 72 children vs 12 [17%] of 69 children) than did children in the non-efavirenz group (table 3). 
Abnormal dreaming was less frequently reported among children in the efavirenz group than among children in 
the non-efavirenz group (table 3). 
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Table 2. Behavioural and neurocognitive test scores 
Item 
Non-efavirenz (n=69) Efavirenz (n=72) Crude model 
 
Adjusted model 
 
  
Mean difference (95% CI) P-value Mean difference (95% CI) P-value 
Child Behaviour Checklist competence scores* 
      Total Competence 23·6 (4·1) 23·4 (4·1) -0·12 (-1·49 to 1·25) 0·86 -2·43 (-4·19 to -0·67) 0·0071 
Activities 10·4 (2·7) 10·4 (2·2) 0·08 (-0·74 to 0·91) 0·84 -0·90 (-2·01 to 0·21) 0·11 
Social 8·5 (1·8) 8·9 (2·0) 0·38 (-0·26 to 1·02) 0·24 -0·61 (-1·46 to 0·23) 0·15 
School 4·7 (0·9) 4·1 (1·3) -0·59 (-0·97 to -0·22) 0·0022 -0·91 (-1·42 to -0·40) 0·00055 
       Child Behaviour Checklist problem score 
      Total problems 25·3 (13·0) 27·4 (17·6) 2·07 (-3·11 to 7·25) 0·43 5·96 (-1·12 to 13·04) 0·098 
Internalizing problems 8·0 (3·9) 9·6 (5·8) 1·60 (-0·06 to 3·25) 0·058 2·00 (-0·29 to 4·29) 0·086 
Externalizing problems 5·8 (4·7) 5·7 (5·5) -0·15 (-1·85 to 1·56) 0·87 0·78 (-1·55 to 3·11) 0·51 
Other problems 
      Social problems 3·0 (2·4) 3·1 (2·8) 0·08 (-0·79 to 0·96) 0·85 0·61 (-0·61 to 1·83) 0·32 
Thought problems 1·5 (1·9) 1·7 (2·3) 0·19 (-0·51 to 0·88) 0·60 0·81 (-0·16 to 1·78) 0·10 
Attention problems 3·4 (2·7) 3·5 (3·5) 0·11 (-0·93 to 1·14) 0·84 1·19 (-0·21 to 2·59) 0·096 
       Neurocognitive scores 
      Raven's Coloured Progressive Matrices 19·8 (5·5) 22·1 (6·7) 2·33 (0·28 to 4·38) 0·026 1·29 (-1·36 to 3·93) 0·34 
Digit Forwards 6·8 (2·1) 7·3 (2·5) 0·51 (-0·26 to 1·27) 0·19 0·57 (-0·43 to 1·56) 0·26 
Digit Backwards 3·2 (1·6) 3·6 (2·1) 0·47 (-0·16 to 1·1) 0·15 0·46 (-0·34 to 1·26) 0·25 
Data are mean (SD) unless otherwise stated. Data were analysed using ANCOVA, with age, sex, parental loss, HIV disclosure, previous treatment failure, combination 
antiretroviral therapy duration, history of tuberculosis treatment, and previous hospital admission entered as covariates in the adjusted models.  
* One child in the efavirenz group was excluded from the Child Behavior Checklist competence analyses because of missing data.  
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Table 3. Central nervous system symptoms 
 
Non-efavirenz 
(n=69) 
Efavirenz  
(n=72) 
Crude model 
 
Adjusted model 
 
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value 
Abnormal dreaming 44 (64%) 35 (49%) 0·54 (0·27 to 1·05) 0·071 0·32 (0·11 to 0·9) 0·031 
Difficulty going to sleep 9 (13%) 5 (7%) 0·50 (0·16 to 1·57) 0·23 0·29 (0·06 to 1·55) 0·15 
Difficulty staying asleep 21 (30%) 14 (19%) 0·55 (0·25 to 1·2) 0·13 0·35 (0·11 to 1·15) 0·083 
Dizziness or balance 
problems 
15 (22%) 14 (19%) 0·87 (0·38 to 1·97) 0·74 1·01 (0·31 to 3·35) 0·98 
Feelings of uneasiness 12 (17%) 20 (28%) 1·83 (0·81 to 4·1) 0·14 3·45 (1·02 to 11·63) 0·046 
Lack of vivacity* 3 (4%) 5 (7%) 1·64 (0·38 to 7·15) 0·51 .. .. 
Depressed or anxious
† 6 (9%) 17 (24%) 3·25 (1·20 to 8·81) 0·021 .. .. 
Attention problems at school 8 (12%) 19 (26%) 2·73 (1·11 to 6·75) 0·029 6·92 (1·81 to 26·48) 0·0047 
Data are n (%) unless otherwise stated. Presence (yes or no) of symptoms in the week before the study visit 
(including the day of study visit) was reported by the child and caretaker. Data were analysed with multiple 
logistic regression analysis, with age, sex, parental loss, HIV disclosure, previous treatment failure, combination 
antiretroviral therapy duration, history of tuberculosis treatment, and previous hospital admission entered as 
covariates in the adjusted models.  
* Given the small number of events, the adjusted model was not applied.  
† Given the substantial impact of the covariate previous treatment failure on the adjusted model, together with 
the low occurrence of treatment failure in the efavirenz group, no adjusted model was applied.  
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When comparing the prescribed efavirenz dose with the dose recommended in the WHO 2016 guidelines,
3
 we 
observed that 40 (56%) of 71 children in the efavirenz group had been prescribed the recommended dose, with 
28 (39%) of 71 children receiving lower doses and three (4%) of 71 children receiving higher doses than 
recommended (figure). Children in the low-dose efavirenz group did not differ from children in the 
recommended and high-dose efavirenz group in age (p=0·69), sex (p=0·22), or number of children with less than 
40 copies of HIV RNA per mL (p=1·00; appendix p 10). To assess whether under-dosing of efavirenz had 
affected our results, we repeated our analyses after excluding children who were prescribed lower doses than 
recommended by WHO (appendix p 11). In line with our initial analyses, we observed lower competence scores 
in children in the efavirenz group (n=43) than in those in the non-efavirenz group (n=69; adjusted mean 
difference −2·55 [95% CI −4·56 to −0·55], p=0·013) as well as lower school performance scores (adjusted mean 
difference −1·06 [–1·61 to −0·50], p=0·00027; appendix p 11). In addition, children in the efavirenz group had 
higher total problem scores (adjusted mean difference 8·92 [95% CI 1·24–16·60], p=0·023) and internalising 
problem scores (adjusted mean difference 3·11 [0·60–5·63], p=0·016), but no difference in externalising 
problem scores (adjusted mean difference 0·82 [–1·70 to 3·34], p=0·52) compared with children in the non-
efavirenz group (appendix p 11). Post-hoc analyses of the individual internalising syndromes showed that 
children in the efavirenz group had higher scores on anxious and depressed behaviours (adjusted mean difference 
0·84 [95% CI −0·12 to 1·80], p=0·087), withdrawn behaviour (adjusted mean difference 1·17 [–0·11 to 2·44], 
p=0·073), and somatic complaints (adjusted mean difference 1·11 [–0·03 to 2·25], p=0·057) than children in the 
non-efavirenz group (appendix p 11), but these results were not significant. Finally, children in the efavirenz 
group scored higher for thought problems (adjusted mean difference 1·25 [95% CI 0·16–2·34], p=0·025) and 
attention problems (adjusted mean difference 1·60 [0·03–3·17], p=0·046) than did children in the non-efavirenz 
group (appendix p 11). Results for non-adherence (appendix p 9) and cognitive test performance (appendix p 11) 
did not change. Further exclusion of three children who were prescribed higher doses than recommended did not 
substantially alter these findings (appendix p 12) 
.
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Discussion 
 
n this cross-sectional, observational study, we found that efavirenz-based cART was associated with lower total 
competence and school performance scores among long-term treated Tanzanian children with HIV infection than 
was non-efavirenz-based cART. Higher total problem and internalising problem scores were also observed in 
children in the efavirenz group than in those in the non-efavirenz group, although these results were not 
significant. We found no difference in cognitive performance and adherence between children on efavirenz and 
children on alternative cART. Except for externalising problems, the effects on problem scores became more 
pronounced after exclusion of children who received low efavirenz doses. 
 
The most striking findings in our study were the lower competence and school performance scores in children on 
efavirenz than in children on alternative cART. Since groups were equally intelligent (RCPM), and short-term 
and working memory seemed unaffected (digit span), these factors cannot explain the differences in school 
performance. Hence, other factors, such as other neurocognitive problems or mood problems, might have played 
a part. For example, 19 (26%) of 72 children on efavirenz reported problems paying attention at school 
compared with eight (12%) of 69 children in the non-efavirenz group (table 3). Follow-up research into these 
attentional control networks (inhibiting irrelevant distractions, sustaining attention, dividing attention, and 
shifting attention) might be fruitful. 
 
Second, our results suggest that children on efavirenz have increased psychopathology. We observed higher total 
and internalising problems in children on efavirenz than in children on alternative cART, with internalising 
problems being characterised by anxious and affective symptoms. The effects were more pronounced in an 
added subgroup analysis among children who were prescribed doses higher than or equal to WHO recommended 
doses. In addition, children on efavirenz more frequently reported symptoms of depression or anxiety and 
feelings of uneasiness (table 3). Our results differ from findings by Coovadia and colleagues, 
12,
 
13
 who reported no difference in psychopathology, defined by the SDQ, between South African children on 
efavirenz and children on ritonavir-boosted lopinavir. These differences could be partly explained by differences 
in age (with mean age 4·3 years in their population vs 9·6 years in our population), culture, and ethnicity. In 
addition, different psychiatric tools were used to define psychopathology. Both the SDQ and the CBCL are 
considered to be effective screeners for identification of child psychopathology.
24
 The SDQ is shorter, does not 
have a section on school performance, and has slightly lower sensitivity compared with the CBCL.
24
 Subtle, 
internalising symptoms might have been overlooked with the SDQ.
13
 In adults on long-term efavirenz, 
internalising problems, such as symptoms of depression, anxiety, and stress, also dominate the neuropsychiatric 
side-effect profile.
6,25
 Overall, these symptoms seem to be more pronounced in adults than in children, with 
greater consequences for quality of life and treatment discontinuation.
11
 It is possible that children, because of 
differential predisposition to drug side-effects, simply suffer less from CNS side-effects of efavirenz than do 
adults. However, caretakers generally consider internalising problems less problematic because these problems 
are characterised by internal distress, rather than overtly socially negative or disruptive behaviour. These features 
make internalising problems difficult to detect, especially when relying on parent-based or caretaker-based 
reports, as is the case with our study. Finally, children on efavirenz less frequently reported signs of abnormal 
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dreaming than did children on alternative cART (table 3), probably because all children from our study received 
efavirenz for 6 months or more, and this and similar problems are thought to resolve after the first weeks of 
treatment.
13
 Importantly, the course of psychiatric symptoms in children is hard to predict, especially during 
crucial periods such as transition to adolescence and adulthood. For example, our group
25
 recently showed that 
depression scores were reduced in adolescents, but increased in adults, on efavirenz in Tanzania. The increasing 
evidence for higher risks of suicidality among adults on efavirenz than among adults on non-efavirenz-based 
cART emphasises the need for clinical follow-up of neuropsychiatric symptoms in children on efavirenz.
26
 
Finally, in-vitro and animal studies have shown that efavirenz can interfere with cell energy homoeostasis and 
interact with the brain serotonin system.
27
 Serotonin fulfils an important role for brain development, and 
exposure to serotonergic drugs (eg, antidepressants of the class serotonin reuptake inhibitors) during childhood 
or pregnancy has been linked to behavioural and developmental problems.
28
 Future studies are needed to assess 
long-term developmental consequences of paediatric efavirenz. 
 
Exclusion of children on suboptimal efavirenz doses increased group differences in behavioural and emotional 
problems. No specific indications for efavirenz dose reduction were recorded in the clinical files of these 
children. Moreover, we did not observe differences in general characteristics or viral suppression between 
children in the low-dose efavirenz group and the recommended and high-dose efavirenz group. Efavirenz has a 
narrow therapeutic window, and a plasma concentration of less than 1000 ng/mL has been consistently linked to 
virological failure and a plasma concentration of more than 4000 ng/mL has been linked to CNS toxicity.
29
 In 
addition to drug dose, efavirenz exposure is determined by adherence, absorption, and metabolism.
7
 Efavirenz is 
metabolised in the liver by cytochrome P450-2B6 (CYP2B6), and certain genetic variants of this enzyme have 
been strongly associated with higher plasma concentrations. These genetic variants are more common in sub-
Saharan Africa (eg, the 516G→T substitution is prevalent in 48·8% of African ancestry).30 We did not measure 
plasma concentrations of efavirenz in our study, and the results from our subgroup analysis have to be 
interpreted with caution. Nevertheless, they might also support dose dependency of efavirenz-related 
neuropsychiatric symptoms. 
 
The major strength of our study is that, by applying standardised validated paediatric psychiatric tools, we were 
able to comprehensively assess emotions, behaviours, and cognition in a substantially large, representative 
sample of school-aged children with HIV infection in sub-Saharan Africa. Different limitations should also be 
acknowledged. First, we did not measure efavirenz plasma concentrations or CD4 cell counts. Second, we cannot 
completely rule out effects of HIV on the brain in view of the finding that 33 (23%) of 141 children had HIV 
RNA counts of 40–1000 copies per mL (table 1) and data about cumulative exposure and HIV RNA counts in 
the cerebrospinal fluid were unavailable. Third, no blinding was applied. Nevertheless, we consider it unlikely 
that the lack of blinding had an important confounding effect because assessments were highly standardised and 
followed the protocol strictly, and study nurses recorded scores without interpreting behaviour. Finally, the 
cross-sectional observational design of our study comes with limitations, and no causal relationships can be 
identified. Groups differed for several clinical parameters, parental loss, and disclosure of HIV. Overall, the non-
efavirenz group had a more severe clinical course, probably leading to underestimation of the effects of efavirenz 
16 
 
in the crude models. Although we tried to correct for these clinical factors by adding them to our statistical 
models, we cannot rule out underestimation of the severity of the side-effect profile of efavirenz. 
 
In conclusion, use of efavirenz in our paediatric cohort was associated with a mild increase in neuropsychiatric 
symptoms, especially in children who received doses higher than or equal to the WHO recommended doses for 
efavirenz. These findings, together with the pervasive evidence of efavirenz-related side-effects in adults and 
serotonergic properties of efavirenz, highlight the need for roll-out of paediatric formulations of alternative 
antiretroviral drugs. Until then, clinical awareness of neuropsychological symptoms remains warranted for 
children on efavirenz. This clinical awareness requires development of culturally adapted instruments and 
training of more mental health workers, especially in low-income settings, such as Tanzania. If symptoms are 
present in efavirenz-treated children, close follow-up is indicated. Referral for psychosocial support or switching 
to alternative cART should be considered if symptoms persist.  
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Research in context panel 
Evidence before this study 
Neuropsychiatric side-effects of efavirenz in adults with HIV infection are increasingly being acknowledged. 
Whether neuropsychiatric side-effects of efavirenz are also common in children remains unclear. To identify 
paediatric studies on neuropsychiatric side-effects of efavirenz, we searched PubMed on June 6, 2018, using the 
search terms “efavirenz” AND “children”, including relevant synonyms (see appendix p 2 for the extensive 
search strategy). The search was unrestricted by language or publication date and yielded 987 search results. 
After manual title and abstract screening, we selected 158 paediatric studies evaluating clinical outcomes of 
efavirenz. Full-text screening of these papers and relevant references resulted in 39 relevant papers. Two studies 
used paediatric psychiatric assessment tools. One trial compared psychopathology between children receiving 
ritonavir-boosted lopinavir versus efavirenz and found no differences in emotional problem scores between 
groups using the 25-item Strengths and Difficulties Questionnaire (SDQ). Another observational study reported 
better SDQ scores in adolescents on efavirenz than in those on non-efavirenz-containing regimens. By contrast, 
five case reports described severe neuropsychiatric symptoms, including ataxia, psychotic symptoms, and 
seizures, during the course of efavirenz treatment, which were linked to high efavirenz plasma concentrations in 
three papers. The remaining 32 papers reported clinical observations of neuropsychiatric symptoms in trials and 
observational studies, without using psychiatric tools. These studies were largely inconclusive, with some 
showing prevalence of up to 39%. 
 
Added value of this study 
Using validated psychiatric tools, we present the first comprehensive psychiatric evaluation of children with 
HIV infection in sub-Saharan Africa on efavirenz. Our findings show an association between paediatric 
efavirenz and a mild increase in neuropsychiatric symptoms, especially in children on adequate or above 
recommended doses by WHO. 
 
Implications of all the available evidence 
WHO recommends efavirenz as a key component of paediatric HIV treatment. Our findings emphasise the need 
for further paediatric behavioural studies comparing efavirenz with alternative, newer drugs. Meanwhile, early 
detection and  adequate follow-up of neuropsychological symptoms inefavirenz-treated children should be made 
a priority. 
